JP2018510855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510855A5 JP2018510855A5 JP2017545950A JP2017545950A JP2018510855A5 JP 2018510855 A5 JP2018510855 A5 JP 2018510855A5 JP 2017545950 A JP2017545950 A JP 2017545950A JP 2017545950 A JP2017545950 A JP 2017545950A JP 2018510855 A5 JP2018510855 A5 JP 2018510855A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- edetate
- solvate
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 42
- 229940083712 aldosterone antagonist Drugs 0.000 claims 16
- 239000002170 aldosterone antagonist Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 229920001983 poloxamer Polymers 0.000 claims 14
- -1 acrylyl group Chemical group 0.000 claims 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 8
- 239000000839 emulsion Substances 0.000 claims 8
- 229960000502 poloxamer Drugs 0.000 claims 8
- 239000000725 suspension Substances 0.000 claims 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 7
- 239000002738 chelating agent Substances 0.000 claims 7
- 229940009662 edetate Drugs 0.000 claims 7
- 239000002736 nonionic surfactant Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- 229960002256 spironolactone Drugs 0.000 claims 7
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical group CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 3
- 229940048820 edetates Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000000744 eyelid Anatomy 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 229940037001 sodium edetate Drugs 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229960005066 trisodium edetate Drugs 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims 2
- 125000004036 acetal group Chemical group 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001299 aldehydes Chemical group 0.000 claims 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229960005057 canrenone Drugs 0.000 claims 2
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229960000860 dapsone Drugs 0.000 claims 2
- 125000002228 disulfide group Chemical group 0.000 claims 2
- 229960001208 eplerenone Drugs 0.000 claims 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000005462 imide group Chemical group 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 210000004175 meibomian gland Anatomy 0.000 claims 2
- ADZYJDJNIBFOQE-RGKMBJPFSA-N mexrenone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 ADZYJDJNIBFOQE-RGKMBJPFSA-N 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 125000000101 thioether group Chemical group 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 241000282461 Canis lupus Species 0.000 claims 1
- 206010010726 Conjunctival oedema Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 210000002175 goblet cell Anatomy 0.000 claims 1
- 210000003284 horn Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000001365 lymphatic vessel Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127362P | 2015-03-03 | 2015-03-03 | |
| US62/127,362 | 2015-03-03 | ||
| PCT/US2016/020683 WO2016141182A1 (en) | 2015-03-03 | 2016-03-03 | Compositions and methods for treating ocular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510855A JP2018510855A (ja) | 2018-04-19 |
| JP2018510855A5 true JP2018510855A5 (https=) | 2019-04-11 |
| JP6861634B2 JP6861634B2 (ja) | 2021-04-21 |
Family
ID=56848617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545950A Active JP6861634B2 (ja) | 2015-03-03 | 2016-03-03 | 眼疾患を処置するための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10350223B2 (https=) |
| EP (1) | EP3265103B1 (https=) |
| JP (1) | JP6861634B2 (https=) |
| ES (1) | ES2984281T3 (https=) |
| WO (1) | WO2016141182A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140207A1 (en) * | 2018-01-11 | 2019-07-18 | Yee Richard W | Compositions and methods for treating ocular diseases |
| US12161752B2 (en) * | 2019-08-20 | 2024-12-10 | Vishwanath Padmanabhan | Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis |
| WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| CN113577022B (zh) * | 2021-05-18 | 2023-03-17 | 南京欣通瑞亿医药科技有限公司 | 一种氨苯砜类化合物混悬液及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3551554A (en) | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
| US3711602A (en) | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| US4192802A (en) | 1976-06-09 | 1980-03-11 | Ciba-Geigy Corporation | Process for the manufacture of steroid carboxylic acid lactones |
| FI59534C (fi) | 1979-10-31 | 1981-09-10 | Orion Yhtymae Oy | Vaordmedel foer fraemjande av haorvaext och hindrande av mjaell |
| GR74635B (https=) | 1980-08-18 | 1984-06-29 | Merck & Co Inc | |
| USRE32112E (en) | 1981-05-26 | 1986-04-15 | Spironolactone-containing composition and use thereof | |
| IT1194185B (it) | 1983-04-01 | 1988-09-14 | Schiapparelli Farma | Composizione per il trattamento dell'acne |
| ES532317A0 (es) | 1983-05-16 | 1985-11-16 | Merck & Co Inc | Una composicion farmaceutica |
| FR2588755B3 (fr) | 1985-10-21 | 1988-01-22 | Aron Brunetiere Robert | Composition therapeutique a base de spironolactone destinee au traitement des alopecies androgenogenetiques |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| EP0410348A1 (en) | 1989-07-26 | 1991-01-30 | G.D. Searle & Co. | Topical spironolactone composition |
| JPH05331066A (ja) | 1992-05-25 | 1993-12-14 | Toko Yakuhin Kogyo Kk | 尋常性ざ瘡治療用組成物 |
| MX9303557A (es) | 1992-08-06 | 1994-03-31 | Beta Pharm Co | Metodo para la administracion de un antiandrogeno, en particular, espironolactona, a traves de la piel. |
| WO1996040258A2 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| ATE343379T1 (de) | 1998-08-20 | 2006-11-15 | 3M Innovative Properties Co | Sprühverband und wirkstoffabgabesystem |
| AU5460800A (en) | 1999-06-02 | 2000-12-18 | Aviana Biopharm | Pharmaceutical transdermal compositions |
| EP1227804B1 (en) | 1999-11-09 | 2007-08-22 | Pharmacia Corporation | Use of eplerenone for treating restenosis |
| WO2003049745A1 (en) | 2001-12-12 | 2003-06-19 | Pharmacia Corporation | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| PL371437A1 (en) | 2002-01-30 | 2005-06-13 | Pharmacia Corporation | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions |
| EP1509236A4 (en) | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| ATE411010T1 (de) | 2002-12-13 | 2008-10-15 | Jagotec Ag | Topische nanopartikel-spironolacton-formulierung |
| CL2004000574A1 (es) | 2003-03-21 | 2005-02-11 | Pharmacia Corp Sa Organizada B | Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion. |
| WO2006002022A2 (en) | 2004-06-15 | 2006-01-05 | Immusol Incorporated | Compositions and methods useful for the treatment of hyperglycemia |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| JP4969052B2 (ja) | 2005-03-31 | 2012-07-04 | 小林製薬株式会社 | 眼科用組成物 |
| US20100130580A1 (en) * | 2006-01-25 | 2010-05-27 | Aciex Therapeutics, Inc. | Formulations and Methods for Treating Dry Eye |
| GB0615064D0 (en) | 2006-07-28 | 2006-09-06 | Sinclair Pharmaceuticals Ltd | Medicament |
| US7879910B1 (en) | 2006-10-10 | 2011-02-01 | Jan Marini Skin Research, Inc. | Compositions and methods for promoting lush hair growth |
| US20100068301A1 (en) | 2006-11-30 | 2010-03-18 | Hutchinson John H | Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators |
| EP3574909B1 (en) | 2008-01-30 | 2026-03-04 | Imbed Biosciences, Inc. | Polyelectrolyte multilayer comprising silver for wound healing |
| US8318678B2 (en) | 2008-05-30 | 2012-11-27 | Jan Marini Skin Research | Cosmetic compositions |
| US20090325918A1 (en) | 2008-06-16 | 2009-12-31 | Somberg John C | Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action |
| WO2010038234A1 (en) | 2008-10-02 | 2010-04-08 | Taro Pharmaceutical Industries Ltd. | Combination product of spironolactone and doxycycline |
| WO2010096558A1 (en) | 2009-02-18 | 2010-08-26 | Eyeon Particle Sciences Llc | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| CA2769041A1 (en) | 2009-07-18 | 2011-01-27 | Leuko Ophthalmic Technologies Limited | Methods material and systems for producing a contact lens and contact lenses produced using said methods material and systems |
| EP2977084B1 (en) | 2010-05-10 | 2017-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| US20120252756A1 (en) * | 2010-06-25 | 2012-10-04 | Coffey Martin J | Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye |
| WO2012093117A1 (en) | 2011-01-03 | 2012-07-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases |
| US9808529B2 (en) | 2012-05-18 | 2017-11-07 | Luoda Pharma Pty Ltd | Liquid formulation |
| WO2014202744A1 (en) | 2013-06-21 | 2014-12-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning |
-
2016
- 2016-03-03 US US15/555,527 patent/US10350223B2/en active Active
- 2016-03-03 WO PCT/US2016/020683 patent/WO2016141182A1/en not_active Ceased
- 2016-03-03 EP EP16759492.8A patent/EP3265103B1/en active Active
- 2016-03-03 ES ES16759492T patent/ES2984281T3/es active Active
- 2016-03-03 JP JP2017545950A patent/JP6861634B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5421272B2 (ja) | 眼病治療のための組成物及び方法 | |
| JP7460707B2 (ja) | ポリアフロンおよびその眼瞼投与 | |
| Loftsson | Topical drug delivery to the retina: obstacles and routes to success | |
| JP2018510855A5 (https=) | ||
| CN111867560A (zh) | 包含噻吗洛尔的药物组合物 | |
| KR20110123789A (ko) | 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 | |
| CN102421425A (zh) | 用于治疗青光眼的不含磷酸盐的药物组合物 | |
| US20130253019A1 (en) | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye | |
| US20170151266A1 (en) | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| JP6934581B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
| CN106604730A (zh) | 角膜厚度调节剂 | |
| JP6861634B2 (ja) | 眼疾患を処置するための組成物及び方法 | |
| WO2006049250A1 (ja) | 眼内移行性促進水性点眼剤 | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| RS64399B1 (sr) | Kompozicije za lečenje oftalmoloških stanja | |
| EP2777699B1 (en) | Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration | |
| EP2875811A1 (en) | Use of dobesilate for treating ocular haemorrhages | |
| KR20240019817A (ko) | 퇴행성 망막 질환에 사용하기 위한 trpa1 채널 길항제 화합물 | |
| WO2019140207A1 (en) | Compositions and methods for treating ocular diseases | |
| WO2014163142A1 (ja) | 眼科用組成物 | |
| AU2014201375B2 (en) | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions | |
| EA051012B1 (ru) | Соединения, являющиеся антагонистами trpa1 каналов, для применения при дегенеративных заболеваниях сетчатки | |
| HK1242197A1 (en) | Polyaphrons and palpebral administration thereof | |
| JP2007056012A (ja) | 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム |